Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-CHLOR0-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
Disclosed are novel polymorphic trihydrated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide. One embodiment of the present invention is directed to a crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-25 phenyl]-benzenesulfonamide (hereinafter “Compound A_crystalline trihydrate form I”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles (°28), when measured using Cu Ka radiation, at about 4.5, 9.0, 13.6, 13.9, 15.8, 17.8, 18.2, 18.5, 19.1, 19.9, 20A, 21.2, 22.1, 22.7, 24.3, 25.0, 25.6, 26.2, 26.8, 27.3, 27.6, 28.0, 28.8, and 30.8.
1. A crystalline form of a sodium salt of 4-tert-butyl-N[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles, when measured using Cu K α radiation, at about 4.5, 9.1, 18.2, and 19.9 °2θ.
2. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 2 .
3. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum containing peaks at about 1125, 1154, 1596, 1612, 1656, and 1673 cm −1 .
4. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum substantially in accordance with FIG. 4 .
5. A pharmaceutical composition comprising the crystalline form according to claim 1 and a pharmaceutically acceptable carrier.
6. A method of preparing a pharmaceutical composition comprising admixing the crystalline form according to claim 1 and a pharmaceutically acceptable carrier.
7. The crystalline form of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles, when measured using Cu K α radiation, at about 4.5, 9.1, 13.6, 13.9, 18.2, 19.9, 22.7, 24.3, 26.8, and 28.0 °2θ.
8. The crystalline form of claim 3 , wherein the crystalline form provides a Raman spectrum containing peaks at about 668, 743, 1125, 1154, 1286, 1587, 1596, 1612, 1656, and 1673 cm −1 .
9. The crystalline form of claim 1 , having a differential scanning calorimetry onset endotherm at about 72.2 °C.
10. The crystalline form of claim 2 , having a differential scanning calorimetry onset endotherm at about 72.2 °C.